Kenneth K Wang

List of Publications by Year
in descending order

217 papers	14,080 citations	31949 53 h-index	21521 114 g-index
221 all docs	221 docs citations	221 times ranked	6623 citing authors

#	Article	IF	Citations
1	Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. American Journal of Gastroenterology, 2008, 103, 788-797.	0.2	1,348
2	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. New England Journal of Medicine, 2009, 360, 2277-2288.	13.9	1,348
3	A critical review of the diagnosis and management of Barrettâ€™s esophagus: the ACA Chicago Workshop1 1Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz Jankowski, Gastroenterology, 2004, 127, 310-330.	0.6	579
4	Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointestinal Endoscopy, 2005, 62, 488-498.	0.5	503
5	Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. Gastroenterology, 2011, 141, 460-468.	0.6	432
6	Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology, 2001, 120, 1630-1639.	0.6	419
7	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
8	Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointestinal Endoscopy, 2007, 66, 460-468.	0.5	338
9	Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology, 2002, 122, 1101-1112.	0.6	334
10	Endoscopic and Surgical Treatment of Mucosal (T1a) Esophageal Adenocarcinoma in Barrett's Esophagus. Gastroenterology, 2009, 137, 815-823.	0.6	329
11	Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients (with video). Gastrointestinal Endoscopy, 2007, 65, 185-195.	0.5	292
12	Long-Term Survival Following Endoscopic and Surgical Treatment of High-Grade Dysplasia in Barrettâ€™s Esophagus. Gastroenterology, 2007, 132, 1226-1233.	0.6	271
13	Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointestinal Endoscopy, 2010, 71, 680-685.	0.5	262
14	Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointestinal Endoscopy, 2000, 52, 328-332.	0.5	256
15	Recurrence of Esophageal Intestinal Metaplasia After Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett's Esophagus: Results From a US Multicenter Consortium. Gastroenterology, 2013, 145, 79-86.e1.	0.6	222
16	Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointestinal Endoscopy, 2001, 54, 682-688.	0.5	214
17	A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. Cancer Research, 2009, 69, 4112-4115.	0.4	202
18	Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointestinal Endoscopy, 2008, 68, 867-876.	0.5	193

#	Article	IF	Citations
19	AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology, 2020, 158, 1776-1786.	0.6	188
20	History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus. Gastroenterology, 2010, 138, 854-869.	0.6	181
21	Bone Morphogenetic Protein 4 Expressed in Esophagitis Induces a Columnar Phenotype in Esophageal Squamous Cells. Gastroenterology, 2007, 132, 2412-2421.	0.6	153
22	Endoscopic Tri-Modal Imaging Is More Effective Than Standard Endoscopy in Identifying Early-Stage Neoplasia in Barrett's Esophagus. Gastroenterology, 2010, 139, 1106-1114.e1.	0.6	149
23	Magnitude of Missed Esophageal Adenocarcinoma After Barrettâ€™s Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 150, 599-607.e7.	0.6	144
24	Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology, 2000, 119, 624-630.	0.6	135
25	Development of Subsquamous High-Grade Dysplasia and Adenocarcinoma After Successful Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology, 2012, 143, 564-566.e1.	0.6	128
26	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrettâ€™s esophagus. Clinical Gastroenterology and Hepatology, 2003, 1, 252-257.	2.4	123
27	Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy, 1995, 42, 59-63.	0.5	121
28	The Effect of Selective Cyclooxygenase-2 Inhibition in Barrett's Esophagus Epithelium: An In Vitro Study. Journal of the National Cancer Institute, 2002, 94, 422-429.	3.0	115
29	Comparative diagnostic performance of volumetric laser endomicroscopy and confocal laser endomicroscopy in the detection of dysplasia associated with Barrettâ€™s esophagus. Gastrointestinal Endoscopy, 2016, 83, 880-888.e2.	0.5	110
30	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clinical Gastroenterology and Hepatology, 2003, 1, 252-257.	2.4	108
31	Late Recurrence of Barrettâ€™s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. Gastroenterology, 2017, 153, 681-688.e2.	0.6	99
32	Factors Associated With Progression of Barrettâ€™s Esophagus: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 1046-1055.e8.	2.4	97
33	Risk of recurrence of Barrettâ€™s esophagus after successful endoscopic therapy. Gastrointestinal Endoscopy, 2016, 83, 1090-1106.e3.	0.5	94
34	Safety and feasibility of volumetric laser endomicroscopy in patients with Barrettâ€™s esophagus (with) Tj ETQq0 0 0 rgBT /Overlock 10	0.5	93
35	A Randomized Comparative Effectiveness Trial of Novel Endoscopic Techniques and Approaches for Barrettâ€™s Esophagus Screening in the Community. American Journal of Gastroenterology, 2015, 110, 148-158.	0.2	92
36	Significance of Neoplastic Involvement of Margins Obtained by Endoscopic Mucosal Resection in Barrett's Esophagus. American Journal of Gastroenterology, 2007, 102, 2380-2386.	0.2	91

#	Article	IF	Citations
37	Current status of photodynamic therapy of Barrett's esophagus. Gastrointestinal Endoscopy, 1999, 49, S20-S23.	0.5	89
38	Increased detection of Barrettâ€™s esophagusâ€“associated neoplasia using wide-area trans-epithelial sampling: aÂmulticenter, prospective, randomized trial. Gastrointestinal Endoscopy, 2018, 87, 348-355.	0.5	87
39	Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy, 2007, 65, 60-66.	0.5	86
40	American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology, 2005, 128, 1471-1505.	0.6	78
41	Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer, 1998, 82, 421-427.	2.0	77
42	Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. Gastroenterology, 2015, 149, 567-576.e3.	0.6	77
43	Utility of Biomarkers in Prediction of Response to Ablative Therapy in Barrett's Esophagus. Gastroenterology, 2008, 135, 370-379.	0.6	76
44	A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Human Pathology, 2008, 39, 1128-1135.	1.1	73
45	Timeline and location of recurrence following successful ablation in Barrettâ€™s oesophagus: an international multicentre study. Gut, 2019, 68, 1379-1385.	6.1	73
46	Obstructive Sleep Apnea Is a Risk Factor for Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 583-588.e1.	2.4	70
47	Use of probeâ€based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence. United European Gastroenterology Journal, 2015, 3, 230-254.	1.6	69
48	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology, 2018, 155, 1720-1728.e4.	0.6	67
49	Breath Testing for Barrettâ€™s Esophagus Using Exhaled Volatile Organic Compound Profiling With an Electronic Nose Device. Gastroenterology, 2017, 152, 24-26.	0.6	63
50	Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasiaâ€“Dysplasiaâ€“Adenocarcinoma Sequence of Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1380-1385.	1.1	60
51	Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus. American Journal of Gastroenterology, 2018, 113, 1156-1166.	0.2	58
52	Safety of Prior Endoscopic Mucosal Resection in Patients Receiving Radiofrequency Ablation of Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2012, 10, 150-154.	2.4	57
53	Cryotherapy for persistent Barrettâ€™s esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2018, 87, 1396-1404.e1.	0.5	56
54	Screening for Barrettâ€™s Esophagus. Gastroenterology, 2015, 148, 912-923.	0.6	54

#	Article	IF	Citations
55	The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus. Journal of Molecular Diagnostics, 2006, 8, 260-267.	1.2	53
56	Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. Oncotarget, 2017, 8, 203-214.	0.8	53
57	Biomarkers in Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 438-446.	1.4	52
58	American Gastroenterological Association Medical Position Statement: Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology, 2005, 128, 1468-1470.	0.6	50
59	Inter-Observer Agreement among Pathologists Using Wide-Area Transepithelial Sampling With Computer-Assisted Analysis in Patients With Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2015, 110, 1257-1260.	0.2	50
60	Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. Clinical Gastroenterology and Hepatology, 2019, 17, 728-738.e9.	2.4	49
61	Notch Signaling Mediates Differentiation in Barrettâ€™s Esophagus and Promotes Progression to Adenocarcinoma. Gastroenterology, 2020, 159, 575-590.	0.6	49
62	Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointestinal Endoscopy, 2015, 82, 46-56.e2.	0.5	48
63	Mechanisms of Disease: carcinogenesis in Barrett's esophagus. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 106-112.	1.7	47
64	Photodynamic Therapy for Gastrointestinal Cancer. Photochemistry and Photobiology, 2020, 96, 517-523.	1.3	47
65	Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointestinal Endoscopy, 2014, 80, 71-77.	0.5	44
66	Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds. World Journal of Gastroenterology, 2016, 22, 1639.	1.4	44
67	Combinatorial Chemoprevention Reveals a Novel Smoothened-Independent Role of GLI1 in Esophageal Carcinogenesis. Cancer Research, 2010, 70, 6787-6796.	0.4	42
68	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clinical Gastroenterology and Hepatology, 2003, 1, 252-7.	2.4	42
69	International, multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in barrett's esophagus (BE): Results of 24-month follow-up. Gastroenterology, 2003, 124, A20.	0.6	41
70	AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Annals of Allergy, Asthma and Immunology, 2020, 124, 416-423.	0.5	41
71	Epidemiology and Outcomes of Young-Onset Esophageal Adenocarcinoma: An Analysis from a Population-Based Database. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 142-149.	1.1	40
72	Effects of Autofluorescence Imaging on Detection and Treatment of Early Neoplasia in Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 774-781.	2.4	39

#	Article	IF	Citations
73	Clinical and Histologic Determinants of Mortality for Patients With Barrettâ€™s Esophagusâ€“Related T1 Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2015, 13, 658-664.e3.	2.4	39
74	EUS-guided verteporfin photodynamic therapy for pancreatic cancer. Gastrointestinal Endoscopy, 2021, 94, 179-186.	0.5	39
75	Endoscopic mucosal resection. Gastrointestinal Endoscopy, 2000, 52, 860-863.	0.5	37
76	Photodynamic therapy in Barrett's esophagus. Gastrointestinal Endoscopy Clinics of North America, 2003, 13, 483-489.	0.6	37
77	Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. Current Opinion in Gastroenterology, 2010, 26, 1.	1.0	37
78	Distinct Role of Kruppel-like Factor 11 in the Regulation of Prostaglandin E2 Biosynthesis. Journal of Biological Chemistry, 2010, 285, 11433-11444.	1.6	37
79	Risk of progression in Barrettâ€™s esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2020, 91, 3-10.e3.	0.5	36
80	Costs associated with Barrettâ€™s esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointestinal Endoscopy, 2018, 87, 88-94.e2.	0.5	35
81	Higher Rate of Barrett's Detection in the First Year After Successful Endoscopic Therapy: Meta-analysis. American Journal of Gastroenterology, 2018, 113, 959-971.	0.2	35
82	Biomarkers in Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 438-446.	1.4	34
83	Photodynamic Therapy of Barrettâ€™s Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2000, 10, 409-419.	0.6	33
84	Mucosal Ablation Therapy of Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 433-437.	1.4	33
85	Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Gastrointestinal Endoscopy, 2020, 92, 31-39.e1.	0.5	33
86	Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer, 2008, 113, 470-476.	2.0	32
87	Persistent intestinal metaplasia after endoscopic eradication therapy of neoplastic Barrettâ€™s esophagus increases the risk of dysplasia recurrence: meta-analysis. Gastrointestinal Endoscopy, 2019, 89, 913-925.e6.	0.5	32
88	Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. Journal of Clinical Gastroenterology, 2019, 53, 361-365.	1.1	31
89	EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses. Gastrointestinal Endoscopy, 2015, 81, 1188-1196.e7.	0.5	30
90	Outcomes of T1b esophageal adenocarcinoma patients. Gastrointestinal Endoscopy, 2011, 74, 1201-1206.	0.5	29

#	Article	IF	Citations
91	Volumetric Laser Endomicroscopy Detects Subsquamous Barrett's Adenocarcinoma. American Journal of Gastroenterology, 2014, 109, 298-299.	0.2	29
92	Photodynamic therapy for Barrettâ€™s esophagus: does light still have a role?. Endoscopy, 2008, 40, 1021-1025.	1.0	28
93	Detection of peritoneal carcinomatosis by EUS fine-needle aspiration: impact on staging and resectability (with videos). Gastrointestinal Endoscopy, 2015, 81, 1215-1224.	0.5	28
94	Accurate Nonendoscopic Detection of Barrett's Esophagus by Methylated DNA Markers: A Multisite Case Control Study. American Journal of Gastroenterology, 2020, 115, 1201-1209.	0.2	28
95	Prospective Evaluation of Adverse Events Following Lower Gastrointestinal Tract EUS FNA. American Journal of Gastroenterology, 2014, 109, 676-685.	0.2	27
96	ASGE EndoVators Summit: simulators and the future of endoscopic training. Gastrointestinal Endoscopy, 2019, 90, 13-26.	0.5	27
97	Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surgical Oncology Clinics of North America, 2002, 11, 321-336.	0.6	25
98	Screening, Surveillance, and Prevention for Esophageal Cancer. Gastroenterology Clinics of North America, 2009, 38, 59-73.	1.0	25
99	Prediction of response to endoscopic therapy of Barrettâ€™s dysplasia by using genetic biomarkers. Gastrointestinal Endoscopy, 2014, 80, 984-991.	0.5	25
100	Remote malignant intravascular thrombi: EUS-guided FNA diagnosis and impact on cancer staging. Gastrointestinal Endoscopy, 2017, 86, 150-155.	0.5	25
101	Predictors of Progression in Barrettâ€™s Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry. American Journal of Gastroenterology, 2017, 112, 867-873.	0.2	25
102	Frozen Section Analysis of Esophageal Endoscopic Mucosal Resection Specimens in the Real-Time Management of Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2006, 4, 173-178.	2.4	23
103	Comparative Outcomes of Cap Assisted Endoscopic Resection and Endoscopic Submucosal Dissection in Dysplastic Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2022, 20, 65-73.e1.	2.4	22
104	Application of artificial intelligence using a novel EUS-based convolutional neural network model to identify and distinguish benign and malignant hepatic masses. Gastrointestinal Endoscopy, 2021, 93, 1121-1130.e1.	0.5	22
105	Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. Journal of Biomedical Optics, 2019, 24, 1.	1.4	22
106	Wide-area transepithelial sampling for dysplasia detection in Barrettâ€™s esophagus: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2022, 95, 51-59.e7.	0.5	21
107	Prevalence and Predictors of Gastroesophageal Reflux Complications in Community Subjects. Digestive Diseases and Sciences, 2016, 61, 3221-3228.	1.1	20
108	NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. Journal of Clinical Medicine, 2020, 9, 2390.	1.0	20

#	Article	IF	Citations
109	Neoplasia Detection Rate in Barrettâ€™s Esophagus and Its Impact on Missed Dysplasia: Results from a Large Population-Based Database. Clinical Gastroenterology and Hepatology, 2021, 19, 922-929.e1.	2.4	20
110	Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma. Human Pathology, 2012, 43, 172-179.	1.1	19
111	Screening and Preventive Strategies in Esophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 163-178.	0.6	18
112	Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. American Journal of Gastroenterology, 2021, 116, 1620-1631.	0.2	18
113	Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus. Chest Surgery Clinics of North America, 2002, 12, 185-203.	0.8	17
114	Endoscopic Evaluation and Advanced Imaging of Barrettâ€™s Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2011, 21, 39-51.	0.6	17
115	Pancreatic cyst epithelial denudation: a natural phenomenon inÂthe absence of treatment. Gastrointestinal Endoscopy, 2016, 84, 788-793.	0.5	17
116	Persistence of Nondysplastic Barrettâ€™s Esophagus Is Not Protective Against Progression to Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2017, 15, 950-952.	2.4	17
117	Recent Advances in Endoscopy. Gastroenterology, 2017, 153, 364-381.	0.6	17
118	Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrettâ€™s esophagus in a multisite case-control study. Gastrointestinal Endoscopy, 2021, 94, 498-505.	0.5	17
119	Limitations of Heartburn and Other Societiesâ€™ Criteria in Barrettâ€™s Screening for Detecting De Novo Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2022, 20, 1709-1718.	2.4	17
120	Complications of Photodynamic Therapy in Gastrointestinal Disease. Gastrointestinal Endoscopy Clinics of North America, 2000, 10, 487-495.	0.6	16
121	Mucosal Ablation Therapy of Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 433-437.	1.4	15
122	Barrettâ€™s Esophagus in 2012: Updates in Pathogenesis, Treatment, and Surveillance. Current Gastroenterology Reports, 2013, 15, 322.	1.1	15
123	A prospective multicenter study using a new multiband mucosectomy device for endoscopic resection of early neoplasia in Barrettâ€™s esophagus. Gastrointestinal Endoscopy, 2018, 88, 647-654.	0.5	15
124	AGA Clinical Practice Update on the Utility of Endoscopic Submucosal Dissection in T1b Esophageal Cancer: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 2161-2166.	2.4	15
125	Feasibility and Safety of Tethered Capsule Endomicroscopy in Patients With Barrettâ€™s Esophagus in a Multi-Center Study. Clinical Gastroenterology and Hepatology, 2022, 20, 756-765.e3.	2.4	15
126	Emerging Concepts for the Endoscopic Management of Superficial Esophageal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 851-860.	0.9	14

#	Article	IF	Citations
127	Computer-aided diagnosis in GI endoscopy: looking into theÂfuture. Gastrointestinal Endoscopy, 2016, 84, 842-844.	0.5	14
128	Assessment of the diagnostic performance and interobserver variability of endocytoscopy in Barrettâ€™s esophagus: A pilotex-vivostudy. World Journal of Gastroenterology, 2013, 19, 8652.	1.4	13
129	Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrettâ€™s esophagus: a propensity scoreâ^'matched cohort study. Gastrointestinal Endoscopy, 2022, 95, 422-431.e2.	0.5	13
130	Mucosal Ablation in Patients with Barrettâ€™s Esophagus: Fry or Freeze?. Digestive Diseases and Sciences, 2018, 63, 2129-2135.	1.1	12
131	Young Adults With Esophageal Adenocarcinoma Present With More Advanced Stage Tumors and Have Shorter Survival Times. Clinical Gastroenterology and Hepatology, 2019, 17, 1756-1762.	2.4	12
132	Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrettâ€™s esophagus. Gastrointestinal Endoscopy, 2021, 93, 1250-1257.e3.	0.5	12
133	Safety and feasibility of same-day discharge after esophageal endoscopic submucosal dissection. Gastrointestinal Endoscopy, 2021, 93, 853-860.	0.5	12
134	CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment. Physics in Medicine and Biology, 2021, 66, 175006.	1.6	12
135	Photodynamic priming with triple-receptor targeted nanoconjugates that trigger T cell-mediated immune responses in a 3D in vitro heterocellular model of pancreatic cancer. Nanophotonics, 2021, 10, 3199-3214.	2.9	12
136	Current strategies in the management of Barrettâ€™s esophagus. Current Gastroenterology Reports, 2005, 7, 196-201.	1.1	11
137	Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. Lasers in Surgery and Medicine, 2012, 44, 755-761.	1.1	11
138	The Risk of Endoscopic Mucosal Resection in the Setting of Clopidogrel Use. ISRN Gastroenterology, 2014, 2014, 1-5.	1.5	11
139	Safety, Diagnostic Accuracy, and Effects of Endoscopic Ultrasound Fine-Needle Aspiration on Detection of Extravascular Migratory Metastases. Clinical Gastroenterology and Hepatology, 2019, 17, 2533-2540.e1.	2.4	11
140	Detection and staging of esophageal cancers. Current Opinion in Gastroenterology, 2004, 20, 381-385.	1.0	10
141	Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 975-981.	1.4	10
142	Radiofrequency Ablation of Barrettâ€™s Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2017, 27, 491-501.	0.6	10
143	Esophageal Epidermoid Metaplasia: Clinical Characteristics and Risk of Esophageal Squamous Neoplasia. American Journal of Gastroenterology, 2021, 116, 1533-1536.	0.2	10
144	Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. Oncotarget, 2015, 6, 32980-33005.	0.8	10

#	Article	IF	Citations
145	How should Barrett?s ulceration be treated?. Surgical Endoscopy and Other Interventional Techniques, 2004, 18, 338-344.	1.3	9
146	Endocytoscopy in Esophageal Cancer. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 273-281.	0.6	9
147	What Constitutes Optimal Management of T1N0 Esophageal Adenocarcinoma?. Annals of Surgical Oncology, 2019, 26, 714-731.	0.7	9
148	Safety and histologic outcomes of endoscopic submucosal dissection with a novel articulating knifeÂforÂesophageal neoplasia. Gastrointestinal Endoscopy, 2020, 91, 797-805.	0.5	9
149	EMR for early stage esophageal cancer: setting the stage for improved patient outcomes. Gastrointestinal Endoscopy, 2003, 58, 244-246.	0.5	8
150	MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus. Journal of Cellular Biochemistry, 2016, 117, 1288-1295.	1.2	8
151	Cytosponge use in risk stratification of Barrett's oesophagus. The Lancet Gastroenterology and Hepatology, 2017, 2, 3-4.	3.7	8
152	Risk factors for serious adverse events associated with multiband mucosectomy in Barrettâ€™s esophagus: an international multicenter analysis of 3827 endoscopic resectionÂprocedures. Gastrointestinal Endoscopy, 2020, 92, 259-268.e2.	0.5	8
153	External validation of blue light imaging (BLI) criteria for the optical characterization of colorectal polyps by endoscopy experts. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2728-2734.	1.4	8
154	Spray cryotherapy prevents need for palliative stenting in patients with esophageal cancer-associated dysphagia. Ecological Management and Restoration, 2022, 35, .	0.2	8
155	Endoscopic Ultrasound Fine-Needle Aspiration Diagnosis of Synchronous Primary Pancreatic Adenocarcinoma and Effects on Staging and Resectability. Clinical Gastroenterology and Hepatology, 2017, 15, 299-302.e4.	2.4	7
156	Smokeless Tobacco and Cigar and/or Pipe Are Risk Factors for Barrett Esophagus in Male Patients With Gastroesophageal RefluxÂDisease. Mayo Clinic Proceedings, 2018, 93, 1282-1289.	1.4	7
157	Accuracy of Endoscopic Ultrasound Imaging in Distinguishing Celiac Ganglia From Celiac Lymph Nodes. Clinical Gastroenterology and Hepatology, 2019, 17, 148-155.e3.	2.4	7
158	NBI in Barrett esophagusâ€”look more and sample less. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 250-251.	8.2	6
159	Tissue-Engineered Cell Sheets for Stricture Prevention: A New Connection Between Endoscopy and Regenerative Medicine. Gastroenterology, 2012, 143, 526-529.	0.6	6
160	319 Recurrence of Intestinal Metaplasia After Eradication of Barrett's Esophagus With Radio Frequency Ablation - Results From a BETRNet Consortium. Gastroenterology, 2012, 142, S-73.	0.6	6
161	Volumetric laser endomicroscopy interpretation and feature analysis in dysplastic Barrett's esophagus. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1761-1765.	1.4	6
162	Outcome of endoscopic mucosal resection in Barrettâ€™s esophagus determined by systematic quantification of epithelial glands using volumetric laser endomicroscopy. Gastrointestinal Endoscopy, 2019, 89, 701-708.e1.	0.5	6

#	Article	IF	Citations
163	Rio de Janeiro Global Consensus on Landmarks, Definitions, and Classifications in Barrettâ€™s Esophagus: World Endoscopy Organization Delphi Study. Gastroenterology, 2022, 163, 84-96.e2.	0.6	6
164	Endoscopic mucosal resection: Esophageal applications. Current Treatment Options in Gastroenterology, 2005, 8, 41-49.	0.3	5
165	Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research. Gastroenterology, 2014, 146, 1586-1590.	0.6	5
166	Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era. Annals of Thoracic Surgery, 2017, 103, 890-897.	0.7	5
167	Editorial: The Effect of Bias on Estimation of Improved Survival After Diagnosis of Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2017, 112, 1265-1266.	0.2	5
168	Esophageal Leukoplakia. ACG Case Reports Journal, 2019, 6, e00213.	0.2	5
169	Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. Clinical Gastroenterology and Hepatology, 2020, 18, 2710-2716.e1.	2.4	5
170	Impact of bariatric surgery on surveillance and treatment outcomes of Barrettâ€™s esophagus: A stage-matched cohort study. Surgery for Obesity and Related Diseases, 2021, 17, 1457-1464.	1.0	5
171	<title>Laser-induced fluorescence in the detection of esophageal carcinoma</title>. , 1995, 2324, 14.		4
172	Management of Barrett's esophagus with high-grade dysplasia. Surgical Clinics of North America, 2002, 82, 683-695.	0.5	4
173	299 Detection of Barrett's Esophagus by Non-invasive Breath Screening of Exhaled Volatile Organic Compounds Using an Electronic-Nose Device. Gastroenterology, 2016, 150, S67.	0.6	4
174	Outcomes of radiofrequency ablation by manual versus self-sizing circumferential balloon catheters for the treatment of dysplastic Barrettâ€™s esophagus: a multicenter comparative cohort study. Gastrointestinal Endoscopy, 2021, 93, 880-887.e1.	0.5	4
175	Expert assessment on volumetric laser endomicroscopy full scans in Barrettâ€™s esophagus patients with or without high grade dysplasia or early cancer. Endoscopy, 2021, 53, 218-225.	1.0	4
176	Optimized Surveillance Intervals Following Endoscopic Eradication of Dysplastic Barrettâ€™s Esophagus: An International Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2763-2771.e3.	2.4	4
177	Combined Endoscopic Mucosal Resection and Photodynamic Therapy for High-Grade Dysplasia and Early Cancer in Barrettâ€™s Esophagus. Techniques in Gastrointestinal Endoscopy, 2005, 7, 69-72.	0.3	3
178	Endoscopic Treatment for Barrettâ€™s Esophagus and Early Esophageal Cancer. Journal of Gastrointestinal Surgery, 2010, 14, 946-947.	0.9	3
179	Tu1120 Obstructive Sleep Apnea is a Risk Factor for Barrett's Esophagus. Gastroenterology, 2012, 142, S-751-S-752.	0.6	3
180	Tu1094 Physician Satisfaction With Current Barrett's Esophagus Surveillance and Acceptability of FISH-Based Testing: A Survey of Gastroenterologists Across the United States. Gastroenterology, 2012, 142, S-744.	0.6	3

#	Article	IF	Citations
181	Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus. Ecological Management and Restoration, 2012, 25, 349-355.	0.2	3
182	A novel method to prevent catheter dysfunction during sprayÂcryotherapy. Gastrointestinal Endoscopy, 2018, 87, 889-890.	0.5	3
183	Screening for Barrett's esophagus. Minerva Medica, 2017, 108, 28-42.	0.3	3
184	Risk Factor Profiles Can Distinguish Esophageal Adenocarcinoma From Barrett's Esophagus. American Journal of Gastroenterology, 2021, 116, 198-201.	0.2	3
185	Photoablation of Barrett's esophagus. Journal of Gastrointestinal Surgery, 2000, 4, 344-345.	0.9	2
186	Endoscopic vs Surgical Resection for Barrett's Intramucosal Adenocarcinoma: Beyond a Therapeutic Equipoise. Gastroenterology, 2012, 143, 257-259.	0.6	2
187	Risk stratification and surveillance in Barrett oesophagus. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 82-84.	8.2	2
188	Editorial: Shining a New Narrow Band of Light on Old Problems. American Journal of Gastroenterology, 2014, 109, 864-866.	0.2	2
189	Longitudinal and Circumferential Distributions of Dysplasia and Early Neoplasia in Barrett's Esophagus: A Pooled Analysis of Three Prospective Studies. Clinical and Translational Gastroenterology, 2021, 12, e00311.	1.3	2
190	Endoscopic submucosal dissection and potential cancer dissemination. Gut, 2022, 71, 236-237.	6.1	2
191	Cryotherapy for Persistent BarrettÊ¼s Dysplasia after Radiofrequency Ablation: If You CanÊ¼t Burn It, Freeze It!. American Journal of Gastroenterology, 2012, 107, S26-S27.	0.2	2
192	Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases. PLoS ONE, 2020, 15, e0243178.	1.1	2
193	Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel. Cancers, 2021, 13, 5781.	1.7	2
194	Spray cryotherapy versus continued radiofrequency ablation in persistent Barrettâ€™s esophagus. Ecological Management and Restoration, 2022, , .	0.2	2
195	Multimodality Therapy for Gastroesophageal Cancers, ,. Journal of Gastrointestinal Surgery, 2002, 6, 527-531.	0.9	1
196	Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2006, 4, 1221-1224.	2.4	1
197	Preface. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, xiii-xiv.	0.6	1
198	Ablation Is in the Eye of the Beholder. Clinical Gastroenterology and Hepatology, 2013, 11, 643-644.	2.4	1

#	Article	IF	Citations
199	The Efficacy of Screening Colonoscopy. JAMA Internal Medicine, 2014, 174, 483.	2.6	1
200	Use of volumetric laser endomicroscopy to characterize aÂduodenal neuroendocrine tumor. Gastrointestinal Endoscopy, 2018, 87, 894-895.	0.5	1
201	Staging of T1 esophageal adenocarcinoma with volumetric laser endomicroscopy: a feasibility study. Endoscopy International Open, 2019, 07, E462-E470.	0.9	1
202	Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Pancreatology, 2020, 20, 110-115.	0.5	1
203	Finding Barrett's oesophagus: is there a machine learning approach in our future?. The Lancet Digital Health, 2020, 2, e6-e7.	5.9	1
204	Scissor-type knife improves the safety of endoscopic submucosal dissection (ESD) among endoscopists without experience in ESD: a randomized ex vivo study. Endoscopy International Open, 2021, 09, E1207-E1213.	0.9	1
205	Surveillance and screening for Barrett's esophagus: What to do when we have so many patients and so little evidence. ASGE Clinical Update, 2005, 13, 1-4.	0.5	0
206	A novel endoscopic oidrs system for non-invasive early diagnosis of esophageal cancers. , 2009, , .		0
207	The essence of management of Barrett's esophagus. Gastrointestinal Endoscopy, 2013, 78, 702-703.	0.5	0
208	Cancer diagnostics: Light scattering by pancreatic cysts. Nature Biomedical Engineering, 2017, 1, .	11.6	0
209	Screening patients for Barrett esophagus: Why, who, and how. Techniques in Gastrointestinal Endoscopy, 2018, 20, 55-61.	0.3	0
210	Response:. Gastrointestinal Endoscopy, 2018, 87, 1595.	0.5	0
211	Endoscopic Treatment of Early Esophageal Neoplasia. , 2019, , 302-315.e2.		0
212	Screening for Barrett's oesophagus: is now the time?. Lancet, The, 2020, 396, 292-293.	6.3	0
213	Diagnostic performance of volumetric laser endomicroscopy for Barrettâ€™s esophagus dysplasia amongst gastroenterology trainees. Translational Gastroenterology and Hepatology, 2022, 7, 0-0.	1.5	0
214	Endoscopic Management of Pre-invasive Esophageal Adenocarcinoma. , 2011, , 227-244.		0
215	Endoscopic Treatment of Superficial Esophageal Cancers. , 2012, , 340-349.		0
216	Inhibition of the BMP pathway prevents development of Barrettâ€™s-associated adenocarcinoma in a surgical rat model. Ecological Management and Restoration, 2021, , .	0.2	0

#	Article	IF	Citations
217	How I Treat Patients With Barrett Esophagus When Endoscopic Ablation Fails. Gastroenterology and Hepatology, 2020, 16, 82-87.	0.2	0